![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Bentham Science Publishers
E-ISSN: 2211-5579|4|2|84-95
ISSN: 2211-5560
Source: Current Psychopharmacology, Vol.4, Iss.2, 2016-02, pp. : 84-95
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
By Smeraldi Enrico Delmonte Dario
Expert Opinion on Drug Safety, Vol. 12, Iss. 6, 2013-11 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Agomelatine has uplifting advantages in depression
Inpharma, Vol. 1, Iss. 1514, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
A Benefit-Risk Assessment of Agomelatine in the Treatment of Major Depression
Drug Safety, Vol. 34, Iss. 9, 2011-09 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Spotlight on Quetiapine in Bipolar Depression
By Keating Gillian M. Robinson Dean M.
CNS Drugs, Vol. 21, Iss. 8, 2007-01 ,pp. :